Bone Allografts in Dentistry
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Medical Policy
Medical Policy Joint Medical Policies are a source for BCBSM and BCN medical policy information only. These documents are not to be used to determine benefits or reimbursement. Please reference the appropriate certificate or contract for benefit information. This policy may be updated and is therefore subject to change. *Current Policy Effective Date: 5/1/21 (See policy history boxes for previous effective dates) Title: Composite Tissue Allotransplantation Description/Background Composite tissue allotransplantation refers to the transplantation of histologically different tissue that may include skin, connective tissue, blood vessels, muscle, bone, and nerve tissue. The procedure is also known as reconstructive transplantation. To date, primary applications of this type of transplantation have been of the hand and face (partial and full), although there are also reported cases of several other composite tissue allotransplantations, including that of the larynx, knee, and abdominal wall. The first successful partial face transplant was performed in France in 2005, and the first complete facial transplant was performed in Spain in 2010. In the United States, the first facial transplant was done in 2008 at the Cleveland Clinic; this was a near-total face transplant and included the midface, nose, and bone. The first hand transplant with short-term success occurred in 1998 in France. However, the patient failed to follow the immunosuppressive regimen, which led to graft failure and removal of the hand 29 months after transplantation. The -
Rapidly Growing Epstein-Barr Virus-Associated Pulmonary Lymphoma After Heart Transplantation
Eur Respir J., 1994, 7, 612–616 Copyright ERS Journals Ltd 1994 DOI: 10.1183/09031936.94.07030612 European Respiratory Journal Printed in UK - all rights reserved ISSN 0903 - 1936 CASE REPORT Rapidly growing Epstein-Barr virus-associated pulmonary lymphoma after heart transplantation M. Schwend*, M. Tiemann**, H.H. Kreipe**, M.R. Parwaresch**, E.G. Kraatz+, G. Herrmann++, R.P. Spielmann$, J. Barth* Rapidly growing Epstein-Barr virus-associated pulmonary lymphoma after heart trans- Dept of *Internal Medicine, **Hemato- plantation. M. Schwend, M. Tiemann, H.H. Kreipe, M.R. Parwaresch, E.G. Kraatz, G. pathology, +Cardiovascular Surgery, Herrmann, R.P. Spielmann, J. Barth. ERS Journals Ltd 1994. ++Cardiology, and $Radiographic Diagnostics, ABSTRACT: There is strong evidence to show an association of Epstein-Barr virus Christian-Albrechts-University of Kiel, Kiel, Germany. (EBV) infection with the development of post-transplant lymphoproliferative dis- ease. We report the rapid development of a malignant lymphoma in a heart trans- Correspondence: J. Barth plant recipient, which occurred within less than eight weeks. I. Medizinische Universitätsklinik The diagnosis of this malignant high grade B-cell lymphoma was established by Schittenhelmstr. 12 open lung biopsy, and classified as centroblastic lymphoma of polymorphic subtype. D-24105 Kiel Immunohistochemically, the lymphoma showed reactivity with the B-cell markers Germany L-26 (CD20) and Ki-B5 and with the activation marker Ber-H2 (CD30). Furthermore, an expression of the bcl-2 oncoprotein was detected. Monoclonal JH gene rearrange- Keywords: Epstein-Barr virus ment was demonstrated by polymerase chain reaction (PCR), indicating monoclonal heart transplantation pulmonary lymphoma proliferation of B-blasts. -
3Rd Quarter 2001 Bulletin
In This Issue... Promoting Colorectal Cancer Screening Important Information and Documentaion on Promoting the Prevention of Colorectal Cancer ....................................................................................................... 9 Intestinal and Multi-Visceral Transplantation Coverage Guidelines and Requirements for Approval of Transplantation Facilities12 Expanded Coverage of Positron Emission Tomography Scans New HCPCS Codes and Coverage Guidelines Effective July 1, 2001 ..................... 14 Skilled Nursing Facility Consolidated Billing Clarification on HCPCS Coding Update and Part B Fee Schedule Services .......... 22 Final Medical Review Policies 29540, 33282, 67221, 70450, 76090, 76092, 82947, 86353, 93922, C1300, C1305, J0207, and J9293 ......................................................................................... 31 Outpatient Prospective Payment System Bulletin Devices Eligible for Transitional Pass-Through Payments, New Categories and Crosswalk C-codes to Be Used in Coding Devices Eligible for Transitional Pass-Through Payments ............................................................................................ 68 Features From the Medical Director 3 he Medicare A Bulletin Administrative 4 Tshould be shared with all General Information 5 health care practitioners and managerial members of the General Coverage 12 provider/supplier staff. Hospital Services 17 Publications issued after End Stage Renal Disease 19 October 1, 1997, are available at no-cost from our provider Skilled Nursing Facility -
Exploring Vigilance Notification for Organs
NOTIFY - E xploring V igilanc E n otification for o rgans , t issu E s and c E lls NOTIFY Exploring VigilancE notification for organs, tissuEs and cElls A Global Consultation e 10,00 Organised by CNT with the co-sponsorship of WHO and the participation of the EU-funded SOHO V&S Project February 7-9, 2011 NOTIFY Exploring VigilancE notification for organs, tissuEs and cElls A Global Consultation Organised by CNT with the co-sponsorship of WHO and the participation of the EU-funded SOHO V&S Project February 7-9, 2011 Cover Bologna, piazza del Nettuno (photo © giulianax – Fotolia.com) © Testi Centro Nazionale Trapianti © 2011 EDITRICE COMPOSITORI Via Stalingrado 97/2 - 40128 Bologna Tel. 051/3540111 - Fax 051/327877 [email protected] www.editricecompositori.it ISBN 978-88-7794-758-1 Index Part A Bologna Consultation Report ............................................................................................................................................7 Part B Working Group Didactic Papers ......................................................................................................................................57 (i) The Transmission of Infections ..........................................................................................................................59 (ii) The Transmission of Malignancies ....................................................................................................................79 (iii) Adverse Outcomes Associated with Characteristics, Handling and Clinical Errors -
Bone Grafting, Its Principle and Application: a Review
OSTEOLOGY AND RHEUMATOLOGY Open Journal PUBLISHERS Review Bone Grafting, Its Principle and Application: A Review Haben Fesseha, MVSc, DVM1*; Yohannes Fesseha, MD2 1Department of Veterinary Surgery and Diagnostic Imaging, School of Veterinary Medicine, Wolaita Sodo University, P. O. Box 138, Wolaita Sodo, Ethiopia 2College of Health Science, School of Medicine, Mekelle University, P. O. Box1871, Mekelle, Ethiopia *Corresponding author Haben Fesseha, MVSc, DVM Assistant Professor, Department of Veterinary Surgery and Diagnostic Imaging, School of Veterinary Medicine, Wolaita Sodo University, P. O. Box: 138, Wolaita Sodo, Ethiopia;; E-mail: [email protected] Article information Received: March 3rd, 2020; Revised: March 20th, 2020; Accepted: April 11th, 2020; Published: April 22nd, 2020 Cite this article Fesseha H, Fesseha Y. Bone grafting, its principle and application: A review. Osteol Rheumatol Open J. 2020; 1(1): 43-50. doi: 10.17140/ORHOJ-1-113 ABSTRACT Bone grafting is a surgical procedure that replaces missing bone through transferring bone cells from a donor to the recipient site and the graft could be from a patient’s own body, an artificial, synthetic, or natural substitute. Bone grafts and bone graft substitutes are indicated for a variety of orthopedic abnormalities such as comminuted fractures (due to car accidents, falling from a height or gunshot injury), delayed unions, non-unions, arthrodesis, osteomyelitis and congenital diseases (rickets, abnormal bone development) and are used to provide structural support and enhance bone healing. Autogenous, allogeneic, and artificial bone grafts are common types and sources of grafts and the advancement of allografts, synthetic bone grafts, and new operative techniques may have influenced the use of bone grafts in recent years. -
MSBCBS Prior Authorization List: Codes to Be Deleted 9/27/10
MSBCBS Prior Authorization List: Codes to be Deleted 9/27/10 FOREHEAD FLAP WITH PRESERVATION OF VASCULAR PEDICLE (EG, AXIAL PATTERN 1 15731 FLAP) ABLATION, CRYOSURGICAL, OF FIBROADENOMA, INCLUDING ULTRASOUND 2 19105 GUIDANCE, EACH FIBROADENOMA COMPUTER-ASSISTED SURGICAL NAVIGATIONAL PROCEDURE FOR MUSCULOSKELETAL PROCEDURES, IMAGE-LESS (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY 3 20985 PROCEDURE) 4 21125 AUGMENTATION, MANDIBULAR BODY OR ANGLE; PROSTHETIC MATERIAL AUGMENTATION, MANDIBULAR BODY OR ANGLE; WITH BONE GRAFT, ONLAY OR 5 21127 INTERPOSITIONAL (INCLUDES OBTAINING AUTOGRAFT) 6 21137 REDUCTION FOREHEAD; CONTOURING ONLY REDUCTION FOREHEAD; CONTOURING AND APPLICATION OF PROSTHETIC MATERIAL 7 21138 OR BONE GRAFT (INCLUDES OBTAINING AUTOGRAFT) REDUCTION FOREHEAD; CONTOURING AND SETBACK OF ANTERIOR FRONTAL SINUS 8 21139 WALL 9 21210 GRAFT, BONE; NASAL, MAXILLARY AND MALAR AREAS (INCLUDES OBTAINING GRAFT) 10 21215 GRAFT, BONE; MANDIBLE (INCLUDES OBTAINING GRAFT) ARTHROPLASTY, TEMPOROMANDIBULAR JOINT, WITH OR WITHOUT AUTOGRAFT 11 21240 (INCLUDES OBTAINING GRAFT) 12 21740 RECONSTRUCTIVE REPAIR OF PECTUS EXCAVATUM OR CARINATUM; OPEN RECONSTRUCTION REPAIR OF PECTUS EXCAVATUM OR CARINATUM; MINIMALLY 13 21742 INVASIVE APPROACH (NUSS PROCEDURE), WITHOUT THORACOSCOPY RECONSTRUCTIVE REPAIR OF PECTUS EXCAVATUM OR CARINATUM; MINIMALLY 14 21743 INVASIVE APPROACH (NUSS PROCEDURE), WITH THORACOSCOPY EXTRACORPOREAL SHOCK WAVE, HIGH ENERGY, PERFORMED BY A PHYSICIAN, REQUIRING ANESTHESIA OTHER THAN LOCAL, INCLUDING ULTRASOUND GUIDANCE, 15 28890 INVOLVING -
AMRITA HOSPITALS AMRITA AMRITA HOSPITALS HOSPITALS Kochi * Faridabad (Delhi NCR) Kochi * Faridabad (Delhi NCR)
AMRITA HOSPITALS HOSPITALS AMRITA AMRITA AMRITA HOSPITALS HOSPITALS Kochi * Faridabad (Delhi NCR) Kochi * Faridabad (Delhi NCR) A Comprehensive A Comprehensive Overview Overview A Comprehensive Overview AMRITA INSTITUTE OF MEDICAL SCIENCES AIMS Ponekkara P.O. Kochi, Kerala, India 682 041 Phone: (91) 484-2801234 Fax: (91) 484-2802020 email: [email protected] website: www.amritahospitals.org Copyright@2018 AMRITA HOSPITALS Kochi * Faridabad (Delhi-NCR) A COMPREHENSIVE OVERVIEW A Comprehensive Overview Copyright © 2018 by Amrita Institute of Medical Sciences All rights reserved. No portion of this book, except for brief review, may be reproduced, stored in a retrieval system, or transmitted in any form or by any means —electronic, mechanical, photocopying, recording, or otherwise without permission of the publisher. Published by: Amrita Vishwa Vidyapeetham Amrita Institute of Medical Sciences AIMS Ponekkara P.O. Kochi, Kerala 682041 India Phone: (91) 484-2801234 Fax: (91) 484-2802020 email: [email protected] website: www.amritahospitals.org June 2018 2018 ISBN 1-879410-38-9 Amrita Institute of Medical Sciences and Research Center Kochi, Kerala INDIA AMRITA HOSPITALS KOCHI * FARIDABAD (DELHI-NCR) A COMPREHENSIVE OVERVIEW 2018 Amrita Institute of Medical Sciences and Research Center Kochi, Kerala INDIA CONTENTS Mission Statement ......................................... 04 Message From The Director ......................... 05 Our Founder and Inspiration Sri Mata Amritanandamayi Devi .................. 06 Awards and Accreditations ......................... -
CIBMTR Scientific Working Committee Research Portfolio July 1, 2018
CIBMTR Scientific July 1, Working Committee 2018 Research Portfolio Milwaukee Campus Minneapolis Campus Medical College of Wisconsin National Marrow Donor Program/ 9200 W Wisconsin Ave, Suite Be The Match – 500 N 5th St C5500 Minneapolis, MN 55401-9959 USA Milwaukee, WI 53226 USA (763) 406-5800 (414) 805-0700 cibmtr.org CIBMTR Scientific Working Committee Research Portfolio: July 1, 2018 TABLE OF CONTENTS 1.0 OVERVIEW .................................................................................................................................................................. 1 1.1 Membership ........................................................................................................................................................... 2 1.2 Leadership .............................................................................................................................................................. 2 1.3 Productivity ............................................................................................................................................................ 3 1.4 How to Get Involved ............................................................................................................................................ 3 2.0 ACUTE LEUKEMIA WORKING COMMITTEE .................................................................................................. 6 2.1 Leadership ............................................................................................................................................................. -
Clinical Considerations in Facial Transplantation
CLINICAL CONSIDERATIONS IN FACIAL TRANSPLANTATION by Anthony Renshaw A thesis submitted in fulfilment of the requirements of University College London for the degree of Doctor of Medicine January 2011 Department of Plastic and Reconstructive Surgery, Academic Division of Surgical & Interventional Sciences, University College London 1 Declaration I, Anthony Renshaw, confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I confirm that this has been indicated in the thesis The copyright of this thesis rests with the author and no quotation from it or information derived from it may be published without the prior written consent of the author. …………………………………………………………. 2 Abstract Facial transplantation has emerged as the next step on the reconstructive ladder for severe facial disfigurement. Clinical issues surrounding facial tissue donation are examined, comprising pre-transplant facial vessel delineation; pre-operative aesthetic matching; and attitudes towards donation. An anatomical study of 200 consecutive facial and transverse facial vessels was performed using colour Doppler ultrasound. Facial vessels were measured at three landmarks and their branching pattern documented. The facial artery main branch was detected at the lower mandibular border in 99.5% of cases, the accompanying facial vein in 97.5%. The transverse facial artery was present in 75.5% of cases, the vein found in 58%. When the facial artery was undetectable, there was transverse facial artery dominance. When the facial vein was absent it was replaced with a transverse facial vein. This provides valuable pre-operative information regarding vessel status. A quantitative eleven- point skin tonal matching scheme is described using digital analysis of facial imagery. -
Consent for Bone Grafting
Consent for Bone Grafting Grafting Procedure: __________________________________________________________________________ I understand that bone grafting and barrier membrane procedures include inherent risks such as, but not limited to the following: 1. Pain. Some discomfort is inherent in any oral surgery procedure. Grafting with materials that do not have to be harvested from your body is less painful because they do not require a donor site surgery, but pos-toperative pain is still likely. It can be largely controlled with pain medications and applying a cold compression to the surgical site. 2. Infection. No matter how carefully surgical sterility is maintained, it is possible, because of the existing non-sterile oral environment, for infections to occur post-operatively. At times these may be a serious nature. Should severe swelling occur, particularly accompanied with fever or malaise, professional attention should be received as soon as possible. 3. Bleeding, bruising, and swelling. Some moderate bleeding may last several hours. If profuse, you must contact us as soon as possible. Some swelling is normal, but if severe, you should notify us. Swelling usually starts to subside after about 48 hours. Bruises may persist for a week or so. 4. Loss of all or part of the graft. Success with bone and membrane grafting is high. Nevertheless, it is possible that the graft could fail. Despite meticulous surgery, particulate bone graft materials can migrate out of the surgery site and be lost. A membrane graft could start to dislodge. If so, the doctor should be notified. You compliance is essential to assure success. 5. Types of graft material. -
78581/2020/Estt-Ne Hr
105 78581/2020/ESTT-NE_HR 1| T a r i f f - AIMS 106 78581/2020/ESTT-NE_HR INDEX 1. General Information ( Section A) 3 i. Out Patient Department ii. Ambulance Charges 2. General Information ( Section B) 5 i. Bed charges ii. In patient Consultation fees iii. Billing Of Surgery Anesthesia and OT Charges iv. Billing Of Surgery /Procedure/ others 3. LAB 9 4. Outsouce Lab 16 5. Blood Bank 64 6. Imaging & Radiodiagnosis 65 7. Non – Invasive Lab 80 8. Anesthesia 82 9. Cardiology and Cardiac Surgery 84 10. Critical Care Services 89 11. Baby Care 91 12. Common Procedure 94 13 Dental 94 14 Dermatology 101 15 E N T 105 16 Gastroenterology 110 17 Maxillo Facial Surgery 113 18 Nephrology 116 19 Neuro Diagnostic Lab 118 20 Oncology 112 21 Ophthalmology 136 22 Orthopedies 142 23 OBS & Gynaecology 149 24 Physiotherapy 154 25 Respiratory Medicine 156 26 Surgery & Major Procedures i. General Surgery 158 ii. Pediatric Surgery 165 iii. PlasticSurgery 170 iv. Neuro Surgery 182 27 Urology 185 28 Interventional Radiology 192 29 Interventional Pain Management 194 30 Paediatric Cardiac Surgery 197 31 Bed Side Service Charges200 2| T a r i f f - AIMS 107 78581/2020/ESTT-NE_HRSection – A GENERAL INFORMATION OUT PATIENT DEPARTMENT OPD Consultations: Superspeciality OPD Consultation * Rs. 700 Specialty OPD Consultation** Rs. 400 to 800 Note: OPD Timing Monday- Saturday ( 8:00AM – 7:00PM) *Super specialty Departments – Cardiac Surgery, Cardiology, Neurology, Neurosurgery, Oncology, Respiratory Medicine, Urology, Plastic Surgery, Gastroenterology, Endocrinology, Paediatric -
Value of Donor–Specific Anti–HLA Antibody Monitoring And
CLINICAL RESEARCH www.jasn.org Value of Donor–Specific Anti–HLA Antibody Monitoring and Characterization for Risk Stratification of Kidney Allograft Loss † †‡ | Denis Viglietti,* Alexandre Loupy, Dewi Vernerey,§ Carol Bentlejewski, Clément Gosset,¶ † † †‡ Olivier Aubert, Jean-Paul Duong van Huyen,** Xavier Jouven, Christophe Legendre, † | † Denis Glotz,* Adriana Zeevi, and Carmen Lefaucheur* Departments of *Nephrology and Kidney Transplantation and ¶Pathology, Saint Louis Hospital and Departments of ‡Kidney Transplantation and **Pathology, Necker Hospital, Assistance Publique Hôpitaux de Paris, Paris, France; †Paris Translational Research Center for Organ Transplantation, Institut National de la Santé et de la Recherche Médicale, UMR-S970, Paris, France; §Methodology Unit (EA 3181) CHRU de Besançon, France; and |University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania ABSTRACT The diagnosis system for allograft loss lacks accurate individual risk stratification on the basis of donor– specific anti–HLA antibody (anti-HLA DSA) characterization. We investigated whether systematic moni- toring of DSA with extensive characterization increases performance in predicting kidney allograft loss. This prospective study included 851 kidney recipients transplanted between 2008 and 2010 who were systematically screened for DSA at transplant, 1 and 2 years post-transplant, and the time of post– transplant clinical events. We assessed DSA characteristics and performed systematic allograft biopsies at the time of post–transplant serum evaluation. At transplant, 110 (12.9%) patients had DSAs; post- transplant screening identified 186 (21.9%) DSA-positive patients. Post–transplant DSA monitoring im- proved the prediction of allograft loss when added to a model that included traditional determinants of allograft loss (increase in c statisticfrom0.67;95%confidence interval [95% CI], 0.62 to 0.73 to 0.72; 95% CI, 0.67 to 0.77).